Find information on thousands of medical conditions and prescription drugs.

Abarelix

Abarelix also called plenaxis is a drug used to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It belongs to the family of drugs called Gonadotropin-releasing hormone antagonists.

A

Acetylcholine chloride

Acetyldigitoxin

Alvircept sudotox

Aminocaproic acid

Aminoglutethimide

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Read more at Wikipedia.org

• [List your site here Free!]



	New treatment for advanced prostate cancer - Updates - Brief Article Men with advanced cases of prostate cancer now have an additional treatment option. In November 2003, the FDA approved Plenaxis (abarelix), a drug given ... From FDA Consumer, 3/1/04

	Insiders Keep Lining Up For Biotech - LITTLE You've got to be selective, but the insider profile remains generally positive in biotech, especially among the smaller, more speculative names. At cardio-device maker Thoratec Corp. (THOR), Direct From First Call/Thomson Financial Insiders' Chronicle, 5/21/01

	ON24 Audio Investor Alert: Amgen VP: Highly Competitive Market Awaits Abarelix Business Editors & Analysts --(BUSINESS WIRE) Amgen Vice President of the Urology Unit is hopeful for Abarelix by the end of the year. For the ... From Business Wire, 6/5/01

	Amgen to Sell GnRH Antagonist Amgen (One Amgen Center Dr., Thousand Oaks, CA 91320; Tel: 805/447-1000, Fax: 805/447-1010, Website: www.amgen.com) and Praecis Pharmaceuticals, Inc. From Applied Genetics News, 4/1/99

	Drug sale for some cancer patients OK'd Medical Briefing Drug sale for some cancer patients OK'd Compiled by Kawanza L. Griffin of the Journal Sentinel staff. Monday, December 1, ... From Milwaukee Journal Sentinel, The, 12/1/03

	Prostate drug gets OK WASHINGTON (AP) -- Certain men with advanced prostate cancer have won access to a new drug to fight pain and other symptoms, an option for those who ... From Deseret News (Salt Lake City), 11/26/03

	PRAECIS PHARMACEUTICALS INCORPORATED Announces German Regulatory Approval for Plenaxis®; Schering AG Collaboration Terminated WALTHAM, Mass. -- PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced that it has received marketing authorization for Plenaxis(R) (abarelix ... From Business Wire, 9/29/05

	PRAECIS PHARMACEUTICALS INCORPORATED Reports First Quarter 2005 Financial Results WALTHAM, Mass. -- PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced consolidated financial results for the three months ended March ... From Business Wire, 5/6/05

Home

Contact

Resources

ebay